Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $294.06 --0%
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Integra Resources raises Florida Canyon reserve 74%, lifts cost guid
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
